| Abstrakt: |
From our real-world experience, BV can induce favourable responses in patients with CD30 SP + sp CTCL and a Canadian pretreatment profile. Dear Editor, Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of non-Hodgkin lymphomas characterized by clonal accumulation of malignant T cells in the skin.1 Brentuximab vedotin (BV) is an antibody-drug conjugate targeted to CD30, which is expressed on neoplastic T cells in primary cutaneous anaplastic large cell lymphoma (pcALCL) and lymphomatoid papulosis (LyP), and variably in mycosis fungoides (MF) and other CTCLs. Four patients (24%) received BV as the last therapy prior to undergoing allogeneic stem cell transplantation (alloSCT) (patients 2, 3, 9 and 10). In patients with MF, 75% (nine of 12) had an objective response (median 3 cycles, IQR 2-4), including the two patients with MF/LyP overlap, with ORR4 in 58% (seven of 12). [Extracted from the article] |
Plný text